AI assistant
Verona Pharma plc — Director's Dealing 2023
Aug 4, 2023
30667_dirs_2023-08-03_1a00168c-5392-4697-b815-cbaec90e8e8d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2023-08-01
Reporting Person: Rickard Kathleen A. (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-08-01 | Ordinary Shares | S | 19736 | $2.679 | Disposed | 2966400 | Direct |
| 2023-08-02 | Ordinary Shares | S | 13728 | $2.593 | Disposed | 2952672 | Direct |
Footnotes
F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2: These sales were effected pursuant to a Rule 10b5-1 instruction entered into on May 14, 2021 solely with the intent to cover taxes in connection with the vesting of certainly previously reported Restricted Share Units.
F3: The price reported represents the sale price of the ADSs divided by eight (8).
F4: Consists of (i) 1,551,792 Ordinary Shares underlying RSUs (which are represented by 193,974 ADSs); and (ii) 1,400,880 Ordinary Shares underlying 175,110 ADSs.